A survey of top executives of U.S. drugmakers indicates mergers and acquisitions should pick up in the next couple of years, as companies aim to offset rising generic competition. The survey by audit and advisory consultants KPMG LLP found 83 percent of pharmaceutical executives believe their company likely will be a buyer or a seller […]

This content is only available to members of the CSBJ.

To gain access, you’ll need to sign in or purchase Digital, Print & Digital Plus, Print & Digital, Print, Digital and The Transcript, Corporate Membership or Digital Monthly

If you’re already a member, sign in here.